Monitor Anastasiou's integration into the executive team and his impact on operational execution. The leadership changes suggest a strategic shift toward strengthening operational capabilities, which could influence future growth initiatives.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $27.74entry
- T+1 · 8mo ago −0.11%α −0.58% · $27.71
- T+5 · 7mo ago +4.15%α +0.53% · $28.89
- T+20 · 7mo ago +12.69%α +2.81% · $31.26
- T+60 · 5mo ago +31.25%α +17.09% · $36.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Harmony Biosciences appointed Peter Anastasiou as Chief Operating Officer and board member Troy Ignelzi, while two directors, including Anastasiou and Antonio Gracias, stepped down. The company disclosed Anastasiou's employment agreement with a $600,000 base salary and $3.7 million equity grant.
Key Facts
- Peter Anastasiou appointed as Senior Executive Vice President and Chief Operating Officer effective April 2, 2026
- Anastasiou resigned from the board of directors upon becoming COO
- Troy Ignelzi appointed to the board to fill Anastasiou's vacancy
- Antonio Gracias will not stand for re-election at the upcoming annual meeting
- Anastasiou's employment agreement includes $600,000 annual base salary
- Anastasiou received an option grant with $3.7 million grant date fair value
- Anastasiou will receive severance equal to one year of base salary if terminated without cause
Financial Impact
The company committed to $600,000 annual cash compensation and $3.7 million in equity compensation for the new COO
Risk Factors
- Potential disruption from leadership transition
- Increased compensation expenses from new executive hire
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-038888 |
| Document: hrmy-20260331x8k.htm | 0001104659-26-038888 |
| Document: hrmy-20260331xex99d1.htm | 0001104659-26-038888 |
| Document: 0001104659-26-038888-index-headers.html | 0001104659-26-038888 |
| Document: 0001104659-26-038888-index.html | 0001104659-26-038888 |
| Document: 0001104659-26-038888.txt | 0001104659-26-038888 |
Track record
20 reports on HRMY
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.82% at T+20 after the Jul 16, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $33.21 Now $32.96 −0.75% settles Dec 15
- Nov 4, 202612d ago 8-K Bearish 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $34.42 Now $32.96 +4.23% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.02 Now $32.96 −10.97% settles Dec 2
- Oct 30, 202617d ago 8-K/A Neutral 3/10 Entry $37.91 Now $32.96 −13.06% settles Dec 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $38.50 Now $32.96 −14.39% settles Nov 25
- Oct 13, 20264w ago 8-K Neutral 3/10 Entry $37.03 to $33.55 Now $32.96 −10.99% ▼ −9.40% −5.79% vs SPY
- Oct 1, 20266w ago Press Release Neutral 3/10 Entry $39.57 to $38.59 Now $32.96 −16.70% ▼ −2.48% −3.18% vs SPY
- Aug 4, 202614w ago 8-K Bullish 7/10 No price data
- Aug 4, 202614w ago Press Release Bullish 6/10 Entry $38.78 Now $32.96 −15.01% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers